Grandview Asset Management LLC Sells 250 Shares of Merck & Co., Inc. (NYSE:MRK)

Grandview Asset Management LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 5.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,100 shares of the company’s stock after selling 250 shares during the quarter. Grandview Asset Management LLC’s holdings in Merck & Co., Inc. were worth $374,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of MRK. Bromfield Sneider Wealth Advisors bought a new position in shares of Merck & Co., Inc. during the 1st quarter worth about $79,000. Hikari Power Ltd raised its holdings in shares of Merck & Co., Inc. by 5.0% in the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock worth $1,939,000 after acquiring an additional 1,130 shares during the last quarter. ACG Wealth raised its holdings in shares of Merck & Co., Inc. by 5.6% in the 1st quarter. ACG Wealth now owns 13,523 shares of the company’s stock worth $1,110,000 after acquiring an additional 722 shares during the last quarter. Mascoma Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 36.4% in the 1st quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock worth $76,000 after acquiring an additional 247 shares during the last quarter. Finally, WealthBridge Investment Counsel Inc. raised its holdings in shares of Merck & Co., Inc. by 4.1% in the 1st quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company’s stock worth $7,206,000 after acquiring an additional 3,475 shares during the last quarter. Institutional investors own 73.33% of the company’s stock.

Merck & Co., Inc. Stock Up 1.1 %

MRK opened at $87.72 on Monday. The company has a 50 day moving average of $89.45 and a 200 day moving average of $87.64. The company has a market cap of $222.22 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 1.18 and a beta of 0.33. Merck & Co., Inc. has a 12 month low of $70.89 and a 12 month high of $95.72. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. The company had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same period last year, the firm earned $1.31 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is 42.27%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Cowen upped their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Cowen upped their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Berenberg Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their target price for the stock from $95.00 to $100.00 in a report on Wednesday, September 14th. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research note on Friday, July 29th. Finally, Mizuho assumed coverage on shares of Merck & Co., Inc. in a research note on Friday, June 24th. They issued a “buy” rating and a $100.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $98.28.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.